• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SEQPWR and SEQOPR: computer programs for design of maximum information trials based on group sequential logrank tests.

作者信息

Kim K

机构信息

Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA.

出版信息

Comput Methods Programs Biomed. 1995 Feb;46(2):143-53. doi: 10.1016/0169-2607(94)01615-m.

DOI:10.1016/0169-2607(94)01615-m
PMID:7796583
Abstract

The maximum information trial paradigm for clinical trials with failure time data was recognized and has been investigated. With the maximum information trial paradigm, a study is concluded when a prespecified maximum number of events of interest, thus maximum information, has been accrued if there was no early stopping due to treatment difference or lack thereof. We present two interactive FORTRAN programs for use in designing maximum information trials based on group sequential logrank tests. The program SEQPWR computes the attainable power of group sequential logrank tests given the combinations of the accrual and follow-up durations. The program SEQOPR allows the users to investigate the operating characteristics of the maximum information trial given the information fractions of interim analyses. A clinical trial from the Eastern Cooperative Oncology Group is provided to illustrate the usage and features of the programs.

摘要

相似文献

1
SEQPWR and SEQOPR: computer programs for design of maximum information trials based on group sequential logrank tests.
Comput Methods Programs Biomed. 1995 Feb;46(2):143-53. doi: 10.1016/0169-2607(94)01615-m.
2
Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.拓扑替康治疗广泛期小细胞肺癌患者的II期研究：一项东部肿瘤协作组试验
J Clin Oncol. 1996 Aug;14(8):2345-52. doi: 10.1200/JCO.1996.14.8.2345.
3
Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.联合顺铂、依托泊苷和伊立替康化疗与拓扑替康单药二线治疗敏感复发性小细胞肺癌患者（JCOG0605）：一项多中心、开放标签、随机 3 期临床试验。
Lancet Oncol. 2016 Aug;17(8):1147-1157. doi: 10.1016/S1470-2045(16)30104-8. Epub 2016 Jun 14.
4
[Irinotecan].[伊立替康]
Nihon Rinsho. 2002 May;60 Suppl 5:339-42.
5
Randomized phase III trial of cisplatin/irinotecan versus cisplatin/etoposide in patients with extensive-stage small-cell lung cancer.顺铂/伊立替康对比顺铂/依托泊苷用于广泛期小细胞肺癌患者的随机III期试验
Clin Lung Cancer. 2006 Mar;7(5):353-6. doi: 10.3816/CLC.2006.n.019.
6
Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group.顺铂/依托泊苷与拓扑替康序贯给药与交替给药作为广泛期小细胞肺癌一线治疗的比较：希腊肿瘤研究小组III期试验的初步结果
Clin Lung Cancer. 2005 Nov;7(3):183-9. doi: 10.3816/CLC.2005.n.034.
7
Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.拓扑替康与顺铂加依托泊苷治疗广泛期小细胞肺癌后观察的比较：E7593——东部肿瘤协作组的一项III期试验
J Clin Oncol. 2001 Apr 15;19(8):2114-22. doi: 10.1200/JCO.2001.19.8.2114.
8
A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.拓扑替康/紫杉醇与依托泊苷/顺铂交替使用及胸部放疗治疗局限期小细胞肺癌的I期研究
Clin Cancer Res. 2003 Jun;9(6):2085-91.
9
Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.伊立替康/顺铂与依托泊苷/顺铂每周交替疗法用于小细胞肺癌患者的I期研究。
Clin Lung Cancer. 2003 Jul;5(1):40-5. doi: 10.3816/CLC.2003.n.020.
10
Italian multicenter phase III randomized study of cisplatin-etoposide with or without bevacizumab as first-line treatment in extensive stage small cell lung cancer: treatment rationale and protocol design of the GOIRC-AIFA FARM6PMFJM trial.
Clin Lung Cancer. 2015 Jan;16(1):67-70. doi: 10.1016/j.cllc.2014.09.001. Epub 2014 Sep 28.